In April the team travelled to AAN in San Diego, where real-world experience with disease-modifying therapies featured prominently on the program. Dr Jack Tsao , Rutgers New Jersey Medical School, Newark, NJ, shared his perspective on lecanemab therapy in patients with mild cognitive impairment and early Alzheimer’s disease, offering practical guidance on integrating treatment into clinical workflows and managing expectations in routine care. Click here for further insights from AAN.

At EAN 2025 in Madrid, there was a strong emphasis on the growing promise of precision medicine. Dr Krystof Bankiewicz , The Ohio State University, Columbus, OH, discussed how advances in gene therapy could help redefine the course of disease for dementias. Alongside this, our congress coverage also highlighted advances in digital tools, imaging and biomarkers, underscoring how technology continues to improve diagnosis and monitoring in these conditions. Explore all the expert interviews from EAN 2025 here .

The year concluded with CTAD 2025, which was a showcase of the latest late-stage clinical trial data and next-generation therapeutic strategies. From next-generation anti-amyloid and anti-tau therapies to new blood-based biomarkers and digital endpoints, the meeting reflected a field in rapid transformation. Our team captured exclusive interviews with investigators leading these efforts, highlighting how translational science is accelerating progress towards more effective, personalised approaches to dementia treatment. Discover all the insights and breakthroughs here .

Across these three major meetings it has become clear that progress in dementia research is accelerating, driven by collaboration, biomarker discovery, and therapeutic diversification. The VJDementia team has been proud to play its part by bringing these expert insights directly to the global community.

Explore all our expert interviews, congress highlights, feature articles and podcasts at VJDementia.com .

If you are interesting in supporting VJDementia they we continue to cover the breakthroughs shaping the future of dementia care, please get in touch .